Form 4: IGM Biosciences Director Acquires Stock Options

Director M Kathleen Behrens acquired stock options for 29,400 shares of IGM Biosciences on March 12, 2024.

Summary

• On March 12, 2024, M Kathleen Behrens, a director of IGM Biosciences, acquired stock options for 29,400 shares.
• The exercise price of these options is $9.95 per share.
• The options vest monthly, with 1/12 of the shares vesting each month following the Issuer's 2024 Annual Meeting of Stockholders, contingent on continued service.
• Full vesting will occur no later than the date of the Issuer's 2025 Annual Meeting of Stockholders.
• The options expire on March 12, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director can be seen as a mildly positive signal, suggesting confidence in the company's future.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule is tied to the Issuer's Annual Meeting of Stockholders in 2024 and 2025, suggesting a focus on long-term service and alignment with shareholder interests.

Industry Context

This is a routine disclosure related to insider transactions, common in publicly traded companies to ensure transparency and compliance with SEC regulations.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates